 |
|
New intranasal influenza vaccine triggers robust immunity with significantly less antigen
October 29, 2008A single administration of a novel, nasally delivered influenza vaccine elicited immune responses in ferrets that were more than 20 times higher than those generated by two injections of the currently approved vaccines, according to a study by NanoBio Corporation. The new vaccine used only half the standard antigen dose to produce this effect.
Results of the study are being presented today at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.
The company's nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines.
"Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity."
In the study, ferrets received 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine (n=12 ferrets/dose). All three doses produced antibody responses substantially higher than those triggered by the standard intramuscular vaccine. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected.
"A large, unmet medical need still exists for protecting people from influenza infection," Baker said. "The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic."
NanoBio plans to begin a phase 1 clinical study for seasonal influenza in the first half of 2009 and is currently initiating preclinical studies in pandemic flu.
MedThink Communications
"Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity."
In the study, ferrets received 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine (n=12 ferrets/dose). All three doses produced antibody responses substantially higher than those triggered by the standard intramuscular vaccine. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected.
"A large, unmet medical need still exists for protecting people from influenza infection," Baker said. "The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic."
NanoBio plans to begin a phase 1 clinical study for seasonal influenza in the first half of 2009 and is currently initiating preclinical studies in pandemic flu.
MedThink Communications
Influenza Vaccine Current Events and Influenza Vaccine News RSSInitial Results Show Pregnant Women Mount Strong Immune Response To One Dose of 2009 H1N1 Flu Vaccine
Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
Flu vaccine given to women during pregnancy keeps infants out of the hospital
Infants born to women who received influenza vaccine during pregnancy were hospitalized at a lower rate than infants born to unvaccinated mothers.
Flu shots not to be sneezed at
Two in five at-risk American adults who would benefit from vaccination against seasonal flu are missing out on the protective shots because they believe they do not need them and are not inclined to be vaccinated.
NIH launches 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women
The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.
NIH prepares to launch 2009 H1N1 influenza vaccine trial in people with asthma
The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.
Early results: In children, 2009 H1N1 influenza vaccine works like seasonal flu vaccine
Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults
We are encouraged by reports that are now emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers.
GEN reports on efforts to quickly develop swine flu vaccine
Scientists around the world are accelerating their efforts to develop a vaccine against the H1N1 influenza virus (Swine flu) as rapidly as possible, reports Genetic Engineering & Biotechnology News (GEN).
Universal flu vaccine holds promise
An influenza vaccine that protects against death and serious complications from different strains of flu is a little closer to reality, Saint Louis University vaccine researchers have found.
Flu virus foiled again
Researchers at The Scripps Research Institute in La Jolla, California, supported in part by the National Institutes of Health, have identified a common Achilles' heel in a wide range of seasonal and pandemic influenza A viruses.
More Influenza Vaccine Current Events and Influenza Vaccine News Articles
 |
Influenza Vaccines for the Future (Birkhäuser Advances in Infectious Diseases) by Rino Rappuoli (Editor), Giuseppe Del Giudice (Editor) The threat constituted by the multiple outbreaks of avian influenza during the last few years is urgently calling for the development of new influenza vaccines. Fortunately, a quantum leap in technology has revolutionized the study of influenza and the engineering of new vaccine strains by reverse genetics. This volume provides a historical background and state-of-the-art information about the recent advances in the biology of influenza and the design of new influenza vaccines. |
 |
60 Minutes - H1N1 (October 18, 2009) Airdate 10/18/09 The H1N1 virus is already setting infection records in this country, and while most people who get this flu can handle it, in some cases, H1N1 can be deadly. Scott Pelley follows the case of 15-year-old Luke Duvall, a high school athlete in intensive care in Little Rock, Arkansas. With staphylococcal pneumonia on top of the H1N1, Luke is on a respirator and fighting for his life. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Vaccines for Pandemic Influenza (Current Topics in Microbiology and Immunology) by Richard W. Compans (Editor), Walter A. Orenstein (Editor) The recent outbreak of disease caused by a novel H1N1 virus has focused global attention on the threat of a new influenza pandemic. Recent years have also seen unprecedented outbreaks of avian influenza A viruses. In particular, highly pathogenic H5N1 viruses have not only resulted in widespread outbreaks in domestic poultry, but have been transmitted to humans resulting in numerous fatalities. The rapid expansion in the geographic distribution of these novel viruses raises the risk that such a virus could cause a global pandemic with high morbidity and mortality. An effective influenza vaccine represents the best approach to prevent and control such an emerging pandemic. However, current influenza vaccines are directed at existing seasonal influenza viruses, which have... |
 |
Homeocare Labs Cold & Flu Relief, 0.3 ounces Tubes (Pack of 2) by Homeocare Labs For the temporary relief of minor fever, chills, runny nose, congestion, body aches and fatigue due to the common cold or the flu. |
 |
Progard-KC Vaccine - 25 Dose Package by INTERVET THIS VACCINE CANNOT BE SHIPPED TO MINNESOTA. One nostril administration of 0.4 ml. is ideal for small breeds or large, fractious dogs. Safe for pregnant bitches and 3 week old puppies. Protects within 72 hours after administration against kennel cough associated with Parainfluenza and Bordetella bronchiseptica. Administer 0.4 ml. intra-nasally in healthy dogs 2 weeks of age or older. Must use within 24 hours once vaccine is reconstituted. |
 |
The Truth About Flu Vaccines Directed By: ITV Also With: ITV (Producer) |
 |
Warning Bird Flu Test Subject Men's Hoodie Sweat Shirt White XXL by 99 Volts |
 |
"Vaccine Alternatives" An Essential Guide for Patients, Parents, Travelers, and Healthcare Workers: How to Prevent and Treat Illness Using Natural Remedies by Ervin Davis (Author) "Immunity is more than immunization." In fact, the vaccines intended to protect you may actually be hindering your body's natural ability to fight biological threats. Do you ever wonder if that annual flu shot does any good at all? Have you ever questioned the wisdom of injecting infants with toxins and live viruses? You're not alone. The chorus of concern about medical vaccines grows louder every year. However, the author wants to do more than tell you what's wrong with all those shots. He wants to point you toward something right. Read this book to find: * A plan for lasting IMMUNITY. * A Clear introduction to herbal healing, hydrotherapy, and other natural remedies. * Detailed plans for preventing and treating common illnesses, The Missing Link. |
 |
The 2007-2012 World Outlook for Influenza Vaccines by Philip M. Parker (Author) This study covers the world outlook for influenza vaccines across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study,... |
 |
60 Minutes - H1N1 (November 1, 2009) Airdate 11/01/09 Where is the vaccine that was supposed to save the nation from the H1N1 virus? Almost 100 people have died from the virus, hospitalizations are on the rise, but the vaccine is still in short supply. Health and Human Services Secretary Kathleen Sebelius tells Scott Pelley that it won't be long before everyone who wants the vaccine will get the vaccine, and she says it is safe and effective. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
| © 2009 BrightSurf.com |